Beneficial effects of acute trans-resveratrol supplementation in treated hypertensive patients with endothelial dysfunction

Clinical and Experimental Hypertension

Volumn 40, Issue 3, 2018, Pages 218-223

  Marques, B C A A ^a,b   Trindade, M ^a   Aquino, J C F ^a   Cunha, A R ^a   Gismondi, R O ^c   Neves, M F ^a   Oigman, W ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^c FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Endothelial dysfunction; Flow mediated dilation; Hypertension; LDL cholesterol; Resveratrol

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESVERATROL; ANTIOXIDANT; STILBENE DERIVATIVE;

ADULT; AGED; AORTIC PRESSURE; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE MEASUREMENT; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FEMALE; FRAMINGHAM RISK SCORE; HEART RATE; HEMODYNAMIC PARAMETERS; HUMAN; HYPERTENSION; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; MALE; MEAN ARTERIAL PRESSURE; MICROCAPSULE; NUTRITIONAL ASSESSMENT; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SHORT COURSE THERAPY; SINGLE DRUG DOSE; SUPPLEMENTATION; SYSTOLIC BLOOD PRESSURE; AORTA; BLOOD; BLOOD PRESSURE; MIDDLE AGED; PATHOPHYSIOLOGY; SEX FACTOR; VASCULAR ENDOTHELIUM; VASODILATATION;

ANTIOXIDANTS; AORTA; BLOOD PRESSURE; BRACHIAL ARTERY; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; SEX FACTORS; STILBENES; VASODILATION;

EID: 85041911145     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641963.2017.1288741     Document Type: Article

References (27)

1. Fulda S., Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov Today. Elsevier Ltd; 2010;15(17–18):757–65.
2. Rius C, Abu-Taha M, Hermenegildo C, Piqueras L, Cerda-Nicolas J-M, Issekutz AC, Estan L, Cortijo J, Morcillo EJ, Orallo F, et al. Trans- but not cis-resveratrol impairs angiotensin-II-mediated vascular inflammation through inhibition of NF-κB activation and peroxisome proliferator-activated receptor-gamma upregulation. J Immunol. 2010;185(6):3718–27.
3. Prasad K., Resveratrol, wine, and atherosclerosis. Int J Angiol. 2012;21(1):7–17.
4. Artaud-Wild SM, Connor SL, Sexton G, Connor WE. Differences in coronary mortality can be explained by differences in cholesterol and saturated fat intakes in 40 countries but not in France and Finland. A paradox. Circulation. 1993;88(6):2771–79.
5. Renaud S, De Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 1992;339:1523–26.
6. Berrougui H, Grenier G, Loued S, Drouin G, Khalil A. A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis. 2009;207(2):420–27.
7. Ghanim H, Sia CL, Abuaysheh S, Korzeniewski K, Patnaik P, Marumganti A, Chaudhuri A, Dandona P. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab. 2010;95(9):1–8.
8. Gurusamy N, Lekli I, Mukherjee S, Ray D, Ahsan MK, Gherghiceanu M, Popescu LM, Das DK. Cardioprotection by resveratrol: A novel mechanism via autophagy involving the mTORC2 pathway. Cardiovasc Res. 2010;86(1):103–12.
9. Holthoff JH, Woodling KA, Doerge DR, Burns ST, Hinson JA, Mayeux PR. Resveratrol, a dietary polyphenolic phytoalexin, is a functional scavenger of peroxynitrite. Biochem Pharmacol. Elsevier Inc.; 2010;80(8):1260–65.
10. Forstermann U. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113:1708–14.
11. Charakida M, Masi S, Luscher TF, Kastelein JJP, Deanfield JE. Assessment of atherosclerosis: the role of flow-mediated dilatation. Eur Heart J. 2010;31:2854–61.
12. Yeboah J, Crouse JR, Hsu F-C, Burke GL, Herrington DM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation. 2007;115(18):2390–97.
13. Wong RHX, Howe PRC, Buckley JD, Coates AM, Kunz I, Berry NM. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis. Elsevier Ltd; 2011;21(11):851–56.
14. Wong RHX, Berry NM, Coates AM, Buckley JD, Bryan J, Kunz I, Howe PRC. Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults. J Hypertens. 2013;31(9):1819–27.
15. Fujitaka K, Otani H, Jo F, Jo H, Nomura E, Iwasaki M, Nishikawa M, Iwasaka T, Das DK. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr Res. Elsevier Inc.; 2011;31(11):842–47.
16. Lekakis J, Rallidis LS, Andreadou I, Vamvakou G, Kazantzoglou G, Magiatis P, Skaltsounis AL, Kremastinos DT. Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2005;12(6):596–600.
17. Carrizzo A, Puca A, Damato A, Marino M, Franco E, Pompeo F, Traficante A, Civitillo F, Santini L, Trimarco V, et al. Resveratrol improves vascular function in patients with hypertension and dyslipidemia by modulating NO metabolism. Hypertension. 2013;62(2):359–66.
18. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117(6):743–53.
19. Heyward VH. Evaluation of body composition. Sports Med. 1996;22(3):146–56.
20. Gallagher D, Adji A, O’Rourke MF. Validation of the transfer function technique for generating central from peripheral upper limb pressure waveform. Am J Hypertens. 2004;17(11):1059–67.
21. Thijssen DHJ, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, Parker B, Widlansky ME, Tschakovsky ME, Green DJ. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol. 2011;300(1):H2–12.
22. Ide T, Tsutsui H, Ohashi N, Hayashidani S, Suematsu N, Tsuchihashi M, Tamai H, Takeshita A. Greater oxidative stress in healthy young men compared with premenopausal women. Arterioscler Thromb Vasc Biol. 2002;22(3):438–42.
23. Barp J, Araújo ASR, Fernandes TRG, Rigatto KV, Llesuy S, Belló-Klein A, Singal P. Myocardial antioxidant and oxidative stress changes due to sex hormones. Braz J Med Biol Res. 2002;35:1075–81.
24. Kander MC, Cui Y, Liu Z. Gender difference in oxidative stress: a new look at the mechanisms for cardiovascular diseases. J Cell Mol Med. 2016;XX(X):1–9.
25. Diehl KJ, Stauffer BL, Greiner JJ, Weil BR, DeSouza CA. Nitric oxide-mediated endothlium-dependent vasodilation is impaired with borderline high-LDL cholesterol. Clin Trans Sci. 2012;5(1):21–26.
26. Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015;114:796–803.
27. Yoshino J, Conte C, Fontana L, Mittendorfer B, Imai SI, Schechtman KB, Gu C, Kunz I, Fanelli F, Patterson B, et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 2012;16(5):658–64.